Oppenheimer reaffirmed their outperform rating on shares of CorMedix (NASDAQ:CRMD – Free Report) in a report issued on Friday, Marketbeat.com reports. Oppenheimer currently has a $13.00 price target on the stock, down from their previous price target of $15.00.
Several other research firms have also commented on CRMD. Citigroup reaffirmed a “market outperform” rating on shares of CorMedix in a research note on Tuesday, November 10th. Royal Bank Of Canada increased their target price on shares of CorMedix from $14.00 to $15.00 and gave the company an “outperform” rating in a research note on Tuesday, November 10th. Weiss Ratings lowered shares of CorMedix from a “hold (c+)” rating to a “hold (c)” rating in a report on Tuesday, November 10th. UBS Group set a $19.00 price target on shares of CorMedix in a research note on Tuesday, November 10th. Finally, Needham & Company LLC lifted their price target on shares of CorMedix from $12.00 to $14.00 and gave the stock a “buy” rating in a research note on Tuesday, November 10th. Eight analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $15.22.
View Our Latest Report on CRMD
CorMedix Stock Performance
CorMedix (NASDAQ:CRMD – Get Free Report) last announced its earnings results on Thursday, November 12th. The company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.07). The company had revenue of $54.52 million during the quarter, compared to analysts’ expectations of $51.76 million. CorMedix had a return on equity of 27.12% and a net margin of 15.49%. Research analysts predict that CorMedix will post 0.52 earnings per share for the current year.
Institutional Trading of CorMedix
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Entropy Technologies LP bought a new stake in shares of CorMedix during the third quarter worth $332,000. Marshall Wace LLP boosted its stake in shares of CorMedix by 53.4% during the third quarter. Marshall Wace LLP now owns 1,195,422 shares of the company’s stock valued at $9,205,000 after purchasing an additional 415,887 shares during the period. Empowered Funds LLC grew its holdings in shares of CorMedix by 10.3% in the third quarter. Empowered Funds LLC now owns 268,323 shares of the company’s stock worth $2,066,000 after purchasing an additional 25,091 shares during the last quarter. Bleakley Financial Group LLC bought a new position in shares of CorMedix in the third quarter worth about $275,000. Finally, First Trust Advisors LP grew its holdings in shares of CorMedix by 609.2% in the third quarter. First Trust Advisors LP now owns 342,855 shares of the company’s stock worth $2,640,000 after purchasing an additional 294,509 shares during the last quarter. Hedge funds and other institutional investors own 34.18% of the company’s stock.
Latest CorMedix News
Here’s some of the latest news about CRMD:
- Positive Sentiment: The planned Heron asset acquisition could add an estimated $125 million–$150 million in pro forma 2027 revenue, with management targeting $45 million–$60 million in annual synergies. Heron assets and synergy outlook
- Neutral Sentiment: Oppenheimer reaffirmed its “outperform” rating but lowered its price target to $13 from $15. The lower target is a downgrade to its outlook, though it remains well above the share price cited in the report. Oppenheimer ratings
- Negative Sentiment: DefenCath pricing pressure is weighing on sales expectations, despite the quarterly revenue beat. CorMedix reported a $14.7 million net loss, and coverage described the earnings result as disappointing; progress with Rezzayo and the Heron transaction are part of the company’s longer-term outlook. Zacks coverage of quarterly results and pricing pressure
About CorMedix
CorMedix Inc. is a biopharmaceutical company focused on products for infectious and inflammatory diseases. Its lead product, DefenCath, is an antimicrobial catheter-lock solution containing taurolidine and heparin. The U.S. Food and Drug Administration approved it to reduce catheter-related bloodstream infections in adults with kidney failure who receive chronic hemodialysis through a central venous catheter. CorMedix expanded its business in 2024 by acquiring Melinta Therapeutics, adding marketed antibiotics to its portfolio.
See Also
- Five stocks we like better than CorMedix
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for CorMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix and related companies with MarketBeat.com's FREE daily email newsletter.
